Eileen W Stalman
A5066545631- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Peripheral Neuropathies and Disorders
- Multiple Sclerosis Research Studies
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- Heparin-Induced Thrombocytopenia and Thrombosis
- Monoclonal and Polyclonal Antibodies Research
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Dermatological and COVID-19 studies
- Viral Infections and Immunology Research
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Respiratory viral infections research
- Psoriasis: Treatment and Pathogenesis
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Myasthenia Gravis and Thymoma
- Cytomegalovirus and herpesvirus research
- Autoimmune Bullous Skin Diseases
- Intramuscular injections and effects
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
Amsterdam University Medical Centers
2021-2025
University of Amsterdam
2021-2025
Amsterdam Neuroscience
2021-2025
Amsterdam UMC Location University of Amsterdam
2022-2024
Sanquin
2022
Reade
2022
Peter Doherty Institute
2022
The University of Melbourne
2022
Vrije Universiteit Amsterdam
2022
Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who often treated immunosuppressive drugs. We aimed to investigate the effect different drugs antibody development after vaccination diseases.In this study, we used serum samples collected from diseases and healthy controls were included two ongoing prospective cohort studies Netherlands. Participants eligible for inclusion substudy if they had been vaccinated any vaccine via Dutch national...
Abstract During the COVID‐19 pandemic, daily life of many patients with dermatological immune‐mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused (fear of) morbidity, mortality associated COVID‐19, vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored impact disease vaccination on DIMIDs, specifically AD, vitiligo. Data from DIMIDs were collected part...
To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated ocrelizumab or fingolimod.This is substudy of prospective multicenter study SARS-CoV-2 immune-mediated diseases. Patients MS ocrelizumab, fingolimod, and no disease-modifying therapies healthy controls were included. The number interferon (IFN)-γ secreting SARS-CoV-2-specific T cells at time points before...
Background Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated ocrelizumab (OCR), a B cell-depleting anti-CD20 monoclonal antibody, is not yet fully understood. Methods In this study, deep immune profiling techniques were employed to investigate the response induced by mRNA untreated MS (n=21), OCR-treated (n=57) and individuals (n=30). Results Among MS, 63% did...
Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for AEs following SARS-CoV-2 vaccination in patients with various immune-mediated inflammatory diseases (IMIDs).
Patients affected by different types of autoimmune diseases, including common conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated with immunosuppressants to suppress disease activity. It is not fully understood how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral cellular immunity induced infection and/or upon vaccination immunosuppressants.The dynamics immune reactivation SARS-CoV-2 experienced MS patients humanized...
Abstract Background The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and unique humans. Although poorly understood, prolonged antigenic stimulation IL‐4‐signaling along the T helper 2‐axis may be instrumental in IgG4 class switching. Recently, repeated SARS‐CoV‐2 mRNA vaccination has been skewing. widely used immunosuppressive drugs have shown only moderately affect humoral responses vaccination, effect on switching not investigated. Methods Here we study impact of such...
Objectives To compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants controls, to investigate determinants for infections. Methods Data were used from an ongoing national prospective multicentre cohort study vaccination responses in IMID Netherlands (Target-to-B! (T2B!) study). Patients wih controls (patients not healthy controls) who completed...
Background Research on the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term prospective data development SARS-CoV-2 antibodies these are lacking. Methods Adult IMIDs from Amsterdam Rheumatology Immunology Center, were invited to participate. All asked recruit their own sex-matched age-matched control subject. Clinical collected via online questionnaires (at baseline, after 1–4 5–9 months follow-up)....
SARS-CoV-2-specific CD8
The objective of this study was to measure humoral responses after SARS-CoV-2 vaccination in MS patients treated with ocrelizumab (OCR) compared without disease modifying therapies (DMTs) relation timing and B-cell count.OCR were divided into an early a late group (cut-off time 12 weeks between infusion first vaccination). Patients vaccinated mRNA-1273 (Moderna). B-cells measured at baseline (time vaccination) antibodies baseline, day 28, 42, 52 70.87 included (62 OCR patients, 29 DMTs). At...
It is unclear which patients with multiple sclerosis (MS) are most susceptible for omicron breakthrough infections.We assessed infections in vaccinated MS and without disease-modifying therapies enrolled an ongoing large prospective study. We longitudinally studied humoral responses after primary booster vaccinations infections.Omicron were reported 110/312 (36%) MS, 105/110 (96%) mild. Omicron occurred more frequently treated anti-CD20 sphingosine-1 phosphate receptor (S1PR) modulators,...
Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time vaccination could predict response SARS-CoV-2 vaccination. In 52 MS, we found be a good predictor for IgG anti-RBD titers (comparable B-cell count). As course may predicted using pharmacokinetic models,...
Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate against a primary infection in unvaccinated IMID patients ISPs. Methods active treatment ISPs controls (i.e. not ISP healthy controls) confirmed before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical...
Abstract Background Repeated mRNA vaccination against SARS-CoV-2 has been shown to induce class switching IgG4, a non-inflammatory human antibody subclass linked tolerance. Although poorly understood, prolonged antigenic stimulation and IL-4 signalling may be instrumental in IgG4 switching. We others have previously that widely used immunosuppressive drugs such as methotrexate (MTX) TNF inhibitors (TNFi) minor inhibitory impact on humoral responses. However, the of is unknown. Aim To study...
During the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, referring to immunity both vaccination and infection might increase responses.This was a substudy of two prospective cohort studies on antibodies RBD-specific IgG titers patients MS healthy controls who had experienced prior first were compared those without...
Abstract Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate against a primary infection in unvaccinated IMID patients ISPs. Methods: active treatment ISPs controls (i.e. not ISP healthy controls) confirmed before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical...
Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated and infections long-term unclear. Methods: Prospective study 60 MS fingolimod measuring humoral up to four vaccinations 8 months fourth vaccination. Results: Anti-WH1 antibody titers increased with each additional At follow-up further most developed new against the BA.1 omicron variant. Conclusion: Repeated boost immunity and, probably...
Background Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and found in patients with rheumatic diseases as well healthy population. Many studies suggest an immune trigger may (transiently) elicit RF responses. However, discrepancies between different make it difficult to determine if which degree reactivity can be triggered by vaccination or infection. Objective We quantitatively explored longitudinal responses after SARS-CoV-2 infection a well-defined, large...